CY1115166T1 - Optimized CD19 Targeted Antibodies - Google Patents

Optimized CD19 Targeted Antibodies

Info

Publication number
CY1115166T1
CY1115166T1 CY20141100264T CY141100264T CY1115166T1 CY 1115166 T1 CY1115166 T1 CY 1115166T1 CY 20141100264 T CY20141100264 T CY 20141100264T CY 141100264 T CY141100264 T CY 141100264T CY 1115166 T1 CY1115166 T1 CY 1115166T1
Authority
CY
Cyprus
Prior art keywords
optimized
antibodies
targeted antibodies
alters
parental antibody
Prior art date
Application number
CY20141100264T
Other languages
Greek (el)
Inventor
Matthew J Bernett
Seung Yup Chu
John R Desjarlais
Sher Bahadur Karki
Gregory Alan Lazar
Erik Weiking Pong
John O Richards
Eugene Alexander Zhukovsky
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07840953.9A external-priority patent/EP2059536B1/en
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of CY1115166T1 publication Critical patent/CY1115166T1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει αντισώματα που στοχεύουν το CD19, όπου τα αντισώματα περιλαμβάνουν τουλάχιστον μια τροποποίηση σχετική με ένα γονικό αντίσωμα, όπου η τροποποίηση μεταβάλει την συγγένεια προς ένα FcgγR ή μεταβάλλει την λειτουργία των τελεστών σε σύγκριση με το γονικό αντίσωμα. Επίσης αποκαλύπτονται μέθοδοι χρήσης των αντισωμάτων της εφεύρεσης.The present invention describes antibodies targeting CD19, wherein the antibodies comprise at least one modification related to a parental antibody, wherein the modification alters the affinity to an FcgγR or alters the function of the effectors relative to the parental antibody. Methods of using the antibodies of the invention are also disclosed.

CY20141100264T 2006-08-14 2014-04-08 Optimized CD19 Targeted Antibodies CY1115166T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82236206A 2006-08-14 2006-08-14
EP07840953.9A EP2059536B1 (en) 2006-08-14 2007-08-14 Optimized antibodies that target cd19

Publications (1)

Publication Number Publication Date
CY1115166T1 true CY1115166T1 (en) 2016-12-14

Family

ID=58449084

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100260T CY1113852T1 (en) 2006-08-14 2013-03-29 OPTIMIZED ANTIBODIES TARGETING TO CD19
CY20141100264T CY1115166T1 (en) 2006-08-14 2014-04-08 Optimized CD19 Targeted Antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100260T CY1113852T1 (en) 2006-08-14 2013-03-29 OPTIMIZED ANTIBODIES TARGETING TO CD19

Country Status (1)

Country Link
CY (2) CY1113852T1 (en)

Also Published As

Publication number Publication date
CY1113852T1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
CY1119641T1 (en) METHODS OF CONSTRUCTION OF IMMOBILINES
CY1121672T1 (en) ANTIBODIES THAT BIND IL-17A AND IL-17F
CY1118592T1 (en) METHODS FOR THE SUSPENSION OF THE INTELLIGENCE COMMITTEE
CY1116632T1 (en) ANTIBODIES DETERMINATORS OF THE HUMAN RECOVERY STAGES
CY1120665T1 (en) HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES OF THEM AND THEIR USES
CY1118349T1 (en) CD19 CONNECTION FACTORS AND THEIR USES
CY1118343T1 (en) TWECK CONNECTION PARTS
CY1119994T1 (en) COMPOSITIONS AND METHODS FOR INCREASING MUSCLE AND MUSCLE POWER COMPETITIVE SPECIFICALLY TON GDF8 AND / OR ACTIVITY
CY1120412T1 (en) ILL-31 SPECIALIZED PARTICULAR PARTS
TR201901841T4 (en) Constant dosing of each antibody.
CR9471A (en) P-CADERINE ANTIBODIES
DE602006006200D1 (en) ANTIBODY AGAINST 25-HYDROXYVITAMINE D
CY1117203T1 (en) SOLUTION "HEAVY CHAIN-MONO" ACCESSORIES
RS52775B (en) Optimized antibodies that target cd19
DK1937721T3 (en) Anti-IL-23 antibodies
CY1110895T1 (en) SYNTHETIC AESTHETIC BATTERY AREAS WITH BATTERY PROPERTIES MODIFIED IN THE MORAL AREAS DIFFERENT FROM AREAS
ATE554105T1 (en) ALTERED ANTIBODIES
CY1119890T1 (en) TREATMENT TREATMENT OF TREATMENT USING SPECIAL ANTI-ANTI-L1
EA201070179A1 (en) ANTIGEN ASSOCIATED WITH LUNG CANCER OPTIONS AND LYMPHOMAS
EA200601670A1 (en) Conjugates of hydroxyalkyl starch and protein
CY1112953T1 (en) USE OF ANTI-CD100 ANTIBODIES
NZ621170A (en) Anti-human cd52 immunoglobulins
CU20120095A7 (en) PCSK9 ANTAGONISTS
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
CY1111649T1 (en) ANTIBODY AGAINST GLYPICAN 3